59.47
전일 마감가:
$56.81
열려 있는:
$57.99
하루 거래량:
64,433
Relative Volume:
2.01
시가총액:
$1.99B
수익:
-
순이익/손실:
$-32.61M
주가수익비율:
-50.64
EPS:
-1.1742
순현금흐름:
-
1주 성능:
-0.73%
1개월 성능:
-8.26%
6개월 성능:
-4.23%
1년 성능:
+29.98%
Belite Bio Inc Adr Stock (BLTE) Company Profile
BLTE을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
BLTE
Belite Bio Inc Adr
|
59.47 | 1.99B | 0 | -32.61M | 0 | -1.1742 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2023-12-14 | 개시 | Maxim Group | Buy |
2023-07-28 | 개시 | Cantor Fitzgerald | Overweight |
2023-07-26 | 개시 | SVB Securities | Outperform |
2022-08-01 | 개시 | H.C. Wainwright | Buy |
2022-07-01 | 개시 | The Benchmark Company | Buy |
Belite Bio Inc Adr 주식(BLTE)의 최신 뉴스
Analysts Issue Forecasts for Belite Bio FY2026 Earnings - Defense World
Reviewing Belite Bio (NASDAQ:BLTE) & ZyVersa Therapeutics (NASDAQ:ZVSA) - Defense World
Bank of America Corp DE Acquires 4,891 Shares of Belite Bio, Inc (NASDAQ:BLTE) - Defense World
Cohen & Company Inc. (NYSEAMERICAN:COHN) Stock Price Crosses Above Two Hundred Day Moving Average – Here’s What Happened - Defense World
Belite Bio, Inc (NASDAQ:BLTE) Shares Sold by Citadel Advisors LLC - Defense World
BNP Paribas Financial Markets Acquires New Shares in Belite Bio, Inc (NASDAQ:BLTE) - Defense World
What is HC Wainwright’s Forecast for Belite Bio Q1 Earnings? - Defense World
What is HC Wainwright's Estimate for Belite Bio Q2 Earnings? - MarketBeat
Belite Bio stock holds $80 target on FDA breakthrough nod By Investing.com - Investing.com Nigeria
Belite Bio stock holds $80 target on FDA breakthrough nod - Investing.com
Belite Bio’s Promising Outlook: FDA Breakthrough Designation and Upcoming Milestones Boost Buy Rating - TipRanks
Yi Chen Recommends Buy Rating for Belite Bio Due to Breakthrough Therapy Designation and Promising Trial Progress - TipRanks
Why Belite Bio’s Stock is Soaring High - TipRanks
Belite Bio’s Tinlarebant Receives FDA Breakthrough Therapy Designation for Stargardt Disease - TipRanks
Belite Bio Says FDA Grants Breakthrough Therapy Tag to Stargardt Disease Drug - marketscreener.com
Belite Bio Announces FDA Granting Of Breakthrough Therapy Designation For Tinlarebant For The Treatment Of Stargardt Disease - marketscreener.com
Belite Bio Receives FDA Breakthrough Therapy Designation for Tinlarebant in Treating Stargardt Disease - Nasdaq
Belite Bio Announces FDA Granting of Breakthrough Therapy - GlobeNewswire
Q2 Earnings Estimate for Belite Bio Issued By HC Wainwright - Defense World
Belite Bio (NASDAQ:BLTE) Earns “Overweight” Rating from Cantor Fitzgerald - Defense World
HC Wainwright Reaffirms Buy Rating for Belite Bio (NASDAQ:BLTE) - Defense World
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - Morningstar
Benchmark maintains Buy on Belite Bio stock, $80 price target unchanged - Investing.com Nigeria
Belite Bio’s Earnings Call Highlights Clinical Progress and Financial Strength - TipRanks
Belite Bio at Deutsche Bank Conference: Promising Drug Trials By Investing.com - Investing.com India
Transcript : Belite Bio, Inc Presents at Deutsche Bank ADR Virtual Investor Conference, May-15-2025 12 - marketscreener.com
Belite Bio at Deutsche Bank Conference: Promising Drug Trials - Investing.com
Belite Bio stock retains Overweight rating at Cantor Fitzgerald - Investing.com Australia
Belite Bio stock retains Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com India
Promising Clinical Trials and Strategic Developments Justify Buy Rating for Belite Bio - TipRanks
Belite Bio Advances Clinical Trials Amid Financial Challenges - TipRanks
Earnings call transcript: Belite Bio’s Q1 2025 sees narrower EPS loss - Investing.com Nigeria
Earnings Flash (BLTE) Belite Bio Q1 Loss $0.45 Vs. FactSet Est. $0.35 Loss - marketscreener.com
Belite Bio Q1 2025 Earnings Call Transcript - MarketBeat
Belite Bio Advances Tinlarebant Trials with Positive Interim Results - TipRanks
Belite Bio, Inc Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update - ADVFN
Belite Bio reports Q1 EPS (45c), consensus (37c) - TipRanks
Belite Bio's Stargardt Disease Drug Passes Critical Phase 3 Trial Review, DSMB Suggests Regulatory Filing - Stock Titan
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025 - GlobeNewswire Inc.
Why Cigna Group Stock Dived Today - The Globe and Mail
Belite Bio, Inc to Present at the dbVICDeutsche Bank ADR Virtual Investor Conference May 15th - GlobeNewswire
Belite Bio to Participate in Four Upcoming Investor Conferences - Stock Titan
Belite Bio (BLTE) to Release Quarterly Earnings on Monday - Defense World
International companies to host live webcasts at Deutsche - GlobeNewswire
UPDATEInternational companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 15, 2025 - The Manila Times
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 15, 2025 - The Manila Times
Belite Bio to Host Webcast on May 14, 2025, to Discuss First Quarter 2025 Financial Results - Stock Titan
The 9 Best Stocks to Buy Now in May (2025)! - The Globe and Mail
Breakthrough: Belite Bio Presents Critical Data from Two Stargardt Disease Clinical Trials at ARVO 2025 - Stock Titan
Belite Bio, Inc (NASDAQ:BLTE) Shares Purchased by JPMorgan Chase & Co. - Defense World
Belite Bio Inc Adr (BLTE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):